GADOTERIDOL

Search structure
Trade Names:
Synonyms:
Status: Approved (1992)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: V08CA04
UNII: 0199MV609F

Physicochemical Descriptors

Property Name Value
Molecular Formula C17H29GdN4O7
Molecular Weight 558.69
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
None Diagnostic agent
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- - - - 2.763
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -7.04--0.37

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Central Nervous System Diseases 3 D002493 ClinicalTrials
Astrocytoma 1 D001254 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 1 D020528 ClinicalTrials
Glioblastoma 1 D005909 ClinicalTrials
Paraganglioma 1 D010235 ClinicalTrials
Glioma 1 D005910 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 1 D020528 ClinicalTrials

Side Effects from Label

Side effects Relative Frequency (%) Labels
Gastrointestinal disorders Dysgeusia 1.43
Gastrointestinal disorders Nausea 1.43
Nervous system disorders Headache 0.68
Nervous system disorders Paraesthesia 0.42
Vascular disorders Hypotension 0.34
General disorders and administration site conditions Injection site pain 0.34
Gastrointestinal disorders Vomiting 0.34
Cardiac disorders Dizziness 0.25
Gastrointestinal disorders Dry mouth 0.25
Skin and subcutaneous tissue disorders Pruritus 0.25
Psychiatric disorders Anxiety 0.17
Skin and subcutaneous tissue disorders Dermatitis 0.17
General disorders and administration site conditions Flushing 0.17
Gastrointestinal disorders Gingivitis 0.17
Eye disorders Lacrimation increased 0.17
Skin and subcutaneous tissue disorders Pruritus 0.17
Skin and subcutaneous tissue disorders Rash 0.17
Infections and infestations Rhinitis 0.17
Immune system disorders Urticaria 0.17
Gastrointestinal disorders Abdominal pain 0.08
Investigations Body temperature increased 0.08
Cardiac disorders Chest pain 0.08
Respiratory, thoracic and mediastinal disorders Cough 0.08
Gastrointestinal disorders Diarrhoea 0.08
Cardiac disorders Dizziness 0.08
Cardiac disorders Dyspnoea 0.08
Investigations Electrocardiogram PR prolongation 0.08
Skin and subcutaneous tissue disorders Erythema 0.08
General disorders and administration site conditions Face oedema 0.08
Nervous system disorders Loss of consciousness 0.08
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness 0.08
Cardiac disorders Nodal rhythm 0.08
Musculoskeletal and connective tissue disorders Nuchal rigidity 0.08
Nervous system disorders Paraesthesia 0.08
Skin and subcutaneous tissue disorders Pruritus 0.08
Skin and subcutaneous tissue disorders Rash maculo-papular 0.08
Vascular disorders Shock 0.08
Psychiatric disorders Staring 0.08
Cardiac disorders Syncope 0.08
Ear and labyrinth disorders Tinnitus 0.08
Gastrointestinal disorders Tongue disorder 0.08
Gastrointestinal disorders Tongue oedema 0.08

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
15.04
General disorders and administration site conditions
10.65
Gastrointestinal disorders
9.75
Vascular disorders
9.75
Immune system disorders
9.2
Respiratory, thoracic and mediastinal disorders
8.17
Skin and subcutaneous tissue disorders
7.55
Cardiac disorders
6.04
Musculoskeletal and connective tissue disorders
5.29
Psychiatric disorders
4.74
Investigations
4.05
Eye disorders
2.68
Injury, poisoning and procedural complications
2.4

Cross References

Resources Reference
CAS NUMBER 120066-54-8
ChEBI 31643
ChEMBL CHEMBL1200593
DrugBank DB00597
FDA SRS 0199MV609F
Human Metabolome Database HMDB14735
PubChem 44144429
SureChEMBL SCHEMBL1650466
CONTENTS